Although these products might confer significant advantages over the currently available treatments, there is still a huge unmet need for drugs that prevent the progression of COPD. Companies are ...

The list for the next round of medicines that ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

Drugmaker AstraZeneca said it intends to cap out-of-pocket prices of four medicines used to treat asthma and chronic obstructive pulmonary disease (COPD) to $35 per month for many patients.

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Medscape Medical News, October 04, 2024 Alert FDA Approves Dupilumab as Add-On for COPD Injectable biologic was approved as adjuvant therapy to inhaled medications. Medscape Medical News ...